Net Income (Loss) Attributable to Parent in USD of Nuvectis Pharma, Inc. from Q1 2021 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Nuvectis Pharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2021 to Q3 2025.
  • Nuvectis Pharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$7.46M, a 79.7% decline year-over-year.
  • Nuvectis Pharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$25.4M, a 31% decline year-over-year.
  • Nuvectis Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$19M, a 14.6% increase from 2023.
  • Nuvectis Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$22.3M, a 16.6% decline from 2022.
  • Nuvectis Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$19.1M, a 48.1% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Nuvectis Pharma, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$25.4M -$7.46M -$3.31M -79.7% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-04
Q2 2025 -$22.1M -$6.33M -$1.91M -43% Apr 1, 2025 Jun 30, 2025 10-Q 2025-11-04
Q1 2025 -$20.2M -$5.33M -$1.16M -27.8% Jan 1, 2025 Mar 31, 2025 10-Q 2025-11-04
Q4 2024 -$19M -$6.25M +$374K +5.65% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-25
Q3 2024 -$19.4M -$4.15M +$1.73M +29.4% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-04
Q2 2024 -$21.1M -$4.43M +$1.28M +22.4% Apr 1, 2024 Jun 30, 2024 10-Q 2025-11-04
Q1 2024 -$22.4M -$4.17M -$122K -3.01% Jan 1, 2024 Mar 31, 2024 10-Q 2025-11-04
Q4 2023 -$22.3M -$6.62M +$74K +1.11% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-25
Q3 2023 -$22.3M -$5.88M -$4K -0.07% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$22.3M -$5.71M -$2.14M -59.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-05
Q1 2023 -$20.2M -$4.05M -$1.11M -37.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-05
Q4 2022 -$19.1M -$6.7M -$4.44M -196% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 -$14.7M -$5.88M -$1.21M -25.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$13.4M -$3.57M +$2.37M +39.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$15.8M -$2.94M -$2.92M -12696% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$12.9M -$2.26M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-08
Q3 2021 -$4.67M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$5.94M Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$23K Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08

Nuvectis Pharma, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$19M +$3.26M +14.6% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-25
2023 -$22.3M -$3.18M -16.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-25
2022 -$19.1M -$6.2M -48.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-05
2021 -$12.9M Jan 1, 2021 Dec 31, 2021 10-K 2023-03-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.